Posted by Michael Wonder on 05 Apr 2021
Copikta (duvelisib) receives positive CHMP opinion for the treatment of relapsed and refractory CLL and refractory FL
1 April 2021 - Secura Bio announced that the CHMP of the EMA adopted a positive opinion recommending the approval of Copiktra as monotherapy for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia after at least two prior therapies and follicular lymphoma that is refractory to at least two prior systemic therapies.
Copiktra is an oral dual inhibitor of the PI3K-delta and gamma pathways, which are involved in the proliferation, growth, and migration of malignant cells and are thought to play a role in the formation and maintenance of a supportive tumour microenvironment.
